- Home
- CRDL vs NATR Comparison
CRDL vs NATR Comparison
Compare CRDL & NATR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRDL | NATR |
|---|---|---|
| Founded | 2017 | 1972 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 226.6M | 220.6M |
| IPO Year | 2017 | 1995 |
Fundamental Metrics
Financial Performance| Metric | CRDL | NATR |
|---|---|---|
| Price | $0.97 | $10.81 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 2 |
| Target Price | $8.55 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 764.3K | 87.7K |
| Earning Date | 11-20-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.00 |
| EPS | N/A | ★ 0.59 |
| Revenue | N/A | ★ $480,144,000.00 |
| Revenue This Year | N/A | $3.24 |
| Revenue Next Year | N/A | $4.74 |
| P/E Ratio | ★ N/A | $21.76 |
| Revenue Growth | N/A | ★ 5.67 |
| 52 Week Low | $0.88 | $11.92 |
| 52 Week High | $2.34 | $28.14 |
Technical Indicators
Market Signals| Indicator | CRDL | NATR |
|---|---|---|
| Relative Strength Index (RSI) | 28.32 | 32.05 |
| Support Level | $0.94 | N/A |
| Resistance Level | $1.10 | $13.04 |
| Average True Range (ATR) | 0.06 | 0.49 |
| MACD | 0.00 | -0.12 |
| Stochastic Oscillator | 20.33 | 35.75 |
Price Performance
Historical ComparisonAbout CRDL Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.
About NATR Nature's Sunshine Products Inc.
Natures Sunshine Products Inc is a natural health and wellness company mainly engaged in the manufacturing and direct selling of nutritional and personal care products. The following Companies' product lines include: General health: Assorted health products related to blood sugar, bone health, cellular health, etc. Immune: offer products that support and strengthen the human immune system, Cardiovascular: Ingredients to give the cardiovascular system optimum support. Digestive: regulates intestinal and digestive functions, Personal care: personal care products for external use, and Weight management: to simplify the weight management process by providing healthy meal replacements. Business segment: Asia, Europe, North America, Latin America, and Other. The majority of revenue is from Asia.